Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.39 |
| ▸ | CFD | P00746 | 7/20 | 0.36 |
| ▸ | F11 | P03951 | 2/20 | 0.35 |
| ▸ | TPSB2 | P20231 | 2/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | VHL | P40337 | 1/20 | 0.34 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516024 | 0.86 | CDK8 (0.36) | IDH1CFDF11TPSB2KLKB1 | |
| SCHEMBL3519281 | 0.80 | IDH1 (0.40) | IDH1CFDF11TPSB2KLKB1 | |
| SCHEMBL3514515 | 0.79 | IDH1 (0.38) | IDH1VHLSYK | |
| SCHEMBL3515909 | 0.78 | MAPT (0.38) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL3515013 | 0.76 | IDH1 (0.41) | IDH1CFDKLKB1FGFR1FGFR2 | |
| SCHEMBL18314572 | 0.75 | IDH1 (0.39) | IDH1CFDF11TPSB2KLKB1 | |
| SCHEMBL3514716 | 0.72 | PRMT5 (0.39) | IDH1CFDF11TPSB2KLKB1 | |
| SCHEMBL3519733 | 0.71 | PRMT5 (0.40) | IDH1CFDVHLLOXL2 | |
| SCHEMBL3519485 | 0.70 | IDH1 (0.40) | IDH1 | |
| SCHEMBL3514825 | 0.70 | IDH1 (0.41) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| WO-2008010964-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | IDH1 963/4885CFD 3645/4885F11 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.